“…These studies provided data on LOR incidence (n = 38), 11 , 23–59 and/or dose escalation incidence (n = 31), 11 , 24 , 26–28 , 31 , 33 , 37–41 , 47–50 , 53–57 , 59–68 and/or dose escalation outcomes (n = 15). 11 , 12 , 27 , 31 , 39 , 50 , 53–56 , 59 , 62 , 66 , 69 , 70 Outcomes for IFX were described in 34 studies. 12 , 23–39 , 49–52 , 56 , 57 , 59–66 , 69 , 70 Outcomes for ADA were described in 23 studies.…”